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Abbreviations 
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CB1: cannabinoid receptor type 1 
CB2: cannabinoid receptor type 2 
CCL2: monocyte chemoattractant protein - MCP1 
CCL4: Chemokine (C-C motif) ligand 4 - Macrophage inflammatory protein-1β - MIP-1β 
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Abstract 
 
Background and aims: Beta-caryophyllene (BCP) is a plant-derived FDA approved food 
additive with anti-inflammatory properties. Some of its beneficial effects in vivo reported to 
involve activation of cannabinoid 2 receptors (CB2) that are predominantly expressed in 
immune cells. Herein, we evaluated the translational potential of BCP using a well-
established model of chronic and binge alcohol-induced liver injury. 
Methods: In this study we investigated the effects of BCP on liver injury induced by chronic 
plus binge alcohol feeding in mice in vivo by using biochemical assays, real-time PCR and 
histology analyses. Serum and hepatic BCP levels were also determined by GC/MS. 
Results: Chronic treatment with BCP attenuated the chronic and binge alcohol-induced liver 
injury and inflammation by attenuating the pro-inflammatory phenotypic `M1` switch of 
Kupffer cells and by decreasing the expression of vascular adhesion molecules ICAM-1, E-
Selectin and P-Selectin, as well as the neutrophil infiltration. It also beneficially influenced 
hepatic metabolic dysregulation (steatosis, protein hyperacetylation, and PPAR-ɑ  signaling). 
The above mentioned protective effects of BCP against alcohol-induced liver injury were 
attenuated in CB2 knockout mice, indicating that the beneficial effects of this natural product 
in liver injury involve CB2 receptor activation. Following acute or chronic administration 
BCP was detectable both in the serum and liver tissue homogenates but not in the brain. 
Conclusions: Given the safety of BCP in humans this food additive has a high translational 
potential in treating or preventing hepatic injury associated with oxidative stress, 
inflammation and steatosis.  
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Introduction 
Beta-caryophyllene (BCP) is a bicyclic sesquiterpene found in larger amounts in 
numerous essential oils of food plants from cloves, basil, and black pepper. Moreover, BCP is 
found in copaiba (Copaifera spp.) and marijuana/hemp (Cannabis spp.), which have been 
used in traditional medicine for centuries due to their anti-inflammatory and analgesic effects 
(Gertsch et al., 2010). Due to its favorable taste and scent and apparent lack of toxicity, BCP 
is approved by the FDA as a food additive for flavoring. BCP, which is devoid of 
psychoactive effects, has been demonstrated to activate cannabinoid 2 receptors (CB2), 
which are primarily expressed in immune and immune-derived cells. This makes BCP a 
promising food-derived agent that may be exploited therapeutically to treat various 
inflammatory diseases (Gertsch et al., 2008). BCP has been reported to exert protective 
effects in experimental animal models of inflammatory pain (Gertsch et al., 2008), kidney 
injury (Horvath et al., 2012b), ischemic stroke (Choi et al., 2013),  Parkinson`s disease (Ojha 
et al., 2016), toxic hepatitis (D-galactosamine- and endotoxin-induced) (Cho et al., 2015), 
experimental liver fibrosis (Mahmoud et al., 2014), and colitis (Bento et al., 2011). BCP has 
been also proposed recently, to exert anti-addictive potential (Al Mansouri et al., 2014). BCP 
has been reported to act on targets other than CB2, involving SIRT-1 (Zheng et al., 2013), 
PPAR-ɑ  (Wu et al., 2014), FAAH, or COX-2 (Chicca et al., 2014). 
Endocannabinoids and cannabinoid receptor signaling play a central role in the 
development of liver diseases by influencing pivotal inflammatory and metabolic pathways 
(Silvestri et al., 2013; Tam et al., 2011; Teixeira-Clerc et al., 2010). Activation of hepatic 
cannabinoid 1 receptor (CB1) by endocannabinoids or synthetic ligands promotes alcoholic- 
(Jeong et al., 2008) and non-alcoholic steatohepatitis (Osei-Hyiaman et al., 2005; Tam et al., 
2012), liver injury (Cao et al., 2013; Horvath et al., 2012a) and fibrosis (Teixeira-Clerc et al., 
2006). In contrast, CB2 receptor activation has tissue protective, anti-inflammatory and 
antifibrotic effects in preclinical models of liver injury, inflammation and fibrosis (Batkai et 
al., 2007; Cao et al., 2013; Horvath et al., 2012a; Louvet et al., 2011; Teixeira-Clerc et al., 
2010). However, despite the promise of selective CB2 receptor agonists in liver disease based 
on preclinical studies, no CB2 agonists are available suitable for human testing in liver 
disease to date. Unlike the potent synthetic CB2 receptor agonists currently used in animal 
models, the phytochemical BCP could be more readily tested in humans as it is a FDA 
approved food additive, thus having immediate translational potential. 
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Inflammation plays a crucial role in the development and progression of alcoholic 
liver disease. In this study, we investigated if BCP treatment exerts beneficial effects against 
liver injury and inflammation induced by chronic plus binge ethanol feeding, and whether 
these effects were mediated via CB2 receptors.  
Materials and Methods 
Animals and Chemicals 
All the animal protocols conformed to the National Institutes of Health (NIH) 
guidelines and were approved by the Institutional Animal Care and use Committee of the 
National Institute on Alcohol Abuse and Alcoholism (Bethesda, MD). The experiments were 
complied with BJP Policy on reporting experiments involving animals and with the principles 
of ARRIVE guidelines. 10-week-old male C57BL/6J mice were obtained from the Jackson 
Laboratory (Bar Harbor, ME). Male CB2
−/− 
mice on C57BL/6J background and their wild-
type controls (CB2
+/+
) were used in the study (termed CB2
−/−
 and CB2
+/+
 mice). 
(E)-beta-caryophyllene (BCP) was obtained as previously described (Gertsch et al., 
2008). Analytical measurements by GC-MS showed that it was 95% pure with beta-
caryophylelne oxide and alpha-humulene as the major impurities. 
Alcoholic Steatohepatitis Model 
Male C57BL/6J mice, weighing more than 20 g were used for ad libitum ethanol 
feeding, as described as the chronic plus binge alcohol feeding-induced steatohepatitis model 
used and developed at the NIAAA (Bertola et al., 2013a).  Lieber-DeCarli ‘82 Shake and 
Pour control liquid diet (Bio-Serv, product no. F1259SP) and Lieber-DeCarli ‘82 Shake and 
Pour ethanol liquid diet (Bio-Serv, product no. F1258SP) were used for diet preparation. 
Mice were fed liquid control diet (Bio-Serv, Frenchtown, NJ) for 5 days, and from day 5 
mice were switched either to a liquid diet containing 5% ethanol for 10 days, or were pair-fed 
a control diet for 10 days. BCP (10mg/kg dose dissolved in DMSO-Tween-Saline in a ratio of 
1:1:18) or vehicle were administered intraperitoneally every day. At day 11, mice in the 
ethanol groups were gavaged with a single dose of ethanol (5 g/kg body weight, 30% 
ethanol), whereas the mice in the control groups were gavaged with isocaloric maltodextrin 
solution. All mice were sacrificed 9 h after gavage. 
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Determination of BCP Pharmacokinetics In Vivo 
We studied the pharmacokinetic properties of BCP, in two set of experiments. To test 
the effect of chronic BCP treatment and the potential influence of ethanol feeding, in a 
separate set of experiments, BCP (10mg/kg/day dose dissolved in DMSO-Tween-Saline in a 
ratio of 1:1:18) or vehicle were administered intraperitoneally to male C57BL/6J mice for 10 
days in accordance with our Lieber-DeCarli ethanol feeding protocol, described above. After 
the administration of the last dose of BCP, liver, brain and serum samples were collected at 
30, 60, 120, and 360 min time points. 
In a separate set of experiment BCP (10mg/kg single dose dissolved in DMSO-
Tween-Saline in a ratio of 1:1:18) or vehicle were administered intraperitoneally or orally to 
male C57BL/6J mice and serum samples were collected at 30, 60, 120, and 360 min after 
drug administration.  
BCP was quantified in liver, kidney, brain and serum. Snap-frozen tissues were weighted and 
transferred into a 2 ml tube containing 3 chrome-steel beads and 0.1 M formic acid and 
homogenized using a mini bead beater (except for the serum). An aliquot of the homogenized 
tissues (100 μl) was rapidly transferred into plastic tube containing 90 μl of ethyl acetate and 
10 μl of α-humulene (used as internal standard), strongly vortexed for 30 seconds and 
sonicated in ice-cold bath for 5 min. Then, samples were centrifuged at max speed for 10 min 
at 4°C and kept for 1 h at -20°C to facilitate the recovery of the upper organic phase. Samples 
were analyzed by gas chromatography (GC)/electron ionization (EI)-mass spectrometry using 
an Agilent 6890 N GC equipped with a 30 m HP-5MS column and a 5975 C EI-MS with 
triple-axis detector. As carrier gas, helium was used at a constant flow rate of 1.0 ml/min with 
splitless injection. Separation of BCP and its internal standard was achieved with the 
following oven program: initial temp. of 100 °C followed by an increase to 120 °C at 
15 °C/min, kept for 0.5 min before increasing to 180°C at 7 °C/min. Oven temperature was 
finally increased to 310°C at 20 °C/min for a total time of 18.9 min. The following specific 
ions were used for selected ion monitoring: m/z 93 for α-humulene and m/z 91 for BCP.  
Determination of Liver Injury 
After venous blood collection, serum was prepared (centrifugation for 10 min at 2500 
G) immediately followed by the determination of the serum levels of alanine 
aminotransferase (ALT) using a clinical chemistry analyzer - Idexx VetTest 8008 (Idexx 
Laboratories, Westbrook, ME, USA). 
Reverse Transcription and Real-Time PCR 
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Hepatic tissues were homogenized in Trizol (Invitrogen, Carlsbad, CA, USA) and 
total RNA was isolated with Direct-zol™ RNA MiniPrep Kit (Zymo Research, Irvine, CA, 
USA). All RNA samples have been DNAse digested, and RNA concentration have been 
measured with NanoDrop (Thermo Scientific, Waltham, MA USA). 2 µg RNA was
, 
reverse-
transcribed (High-Capacity cDNA Reverse Transcription Kit, Applied Biosystems, Foster 
City, CA, USA) and the target genes were amplified using the standard SyberGreen based 
real-time PCR kit (SYBR® Select Master Mix, Applied Biosystems, Foster City, CA). 
Primers sequences are provided in Supplementary Table 1. 
Histology and Immunohistochemistry 
After routine FFPE specimen processing, 5 µm thick liver sections were prepared and 
stained with hematoxylin and eosin (H&E) for histological evaluation of liver injury.  
For immunohistochemistry, deparaffinized sections underwent antigen retrieval (pH=6 citrate 
buffer, at 95 
0
C for 10 min or Proteinase K (20µg/ml in Tris-EDTA buffer pH=8) digestion 
for F4/80 staining, at 37 
0
C for 15 min followed by 10 min additional digestion at room 
temperature). After blocking endogenous peroxidase activity (3% H2O2 solution in PBS), the 
sections were blocked in appropriate sera (2.5% goat, or horse serum in PBS and 2% milk 
powder or bovine serum albumin). Primary antibodies (4-HNE (Japan Institute for the 
Control of Aging, Nikken SEIL Co., Fukuroi, Shizuoka, Japan), Iba-1 (Wako Pure Chemical 
Industries, Chuo-Ku, Osaka, Japan), F4/80 (eBioscience, San Diego, CA, USA), Ly6-G 
(Abcam, Cambridge, MA, USA)) were incubated with the sections overnight in diluted 
blocking solution at 4 
0
C. After primary antibody incubations, the sections were washed three 
times in PBS and incubated for an hour either with biotinylated secondary antibody 
(Vectastain ABC kit, Vector Laboratories, Burlingame, CA, USA) or with an anti-rat 
IgG/anti-rabbit IgG conjugated with a peroxidase polymer (ImmPress reagents, Vector 
Laboratories, Burlingame, CA, USA). Secondary antibodies were washed 3 times for 10 min 
and the specific signal was developed with diaminobenzidine (ImmPACT DAB EqV 
Peroxidase (HRP) Substrate, Vector Laboratories, Burlingame, CA, USA). The specific 
staining was visualized and images were acquired using BX-41 microscope (Olympus, 
Tokyo, Japan).  
For confocal imaging, the sections were incubated with a goat anti-rabbit IgG secondary 
antibody, conjugated to Alexa Fluor® 594 or Alexa Fluor® 488 (Thermo Scientific, 
Waltham, MA USA). Nuclei were stained with the far-red emitting DRAQ5 stain (Cell 
Signaling Technology, Danvers, MA, USA) and visualized under a Zeiss LSM710 confocal 
microscope (Jena, Germany). 
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Liver samples embedded in optimal cutting temperature (OCT) compound were cut (10 µm) 
and stained with Oil Red O (Sigma-Aldrich, St. Louis, MO, USA) dissolved in isopropanol to 
evaluate hepatic lipid accumulation.  
Determination of Hepatic Triglyceride Content 
Triglyceride content was measured from frozen liver tissues by the Triglyceride 
Quantification Colorimetric Kit (Biovision, San Francisco, CA, USA) according to the 
manufacturer’s instructions. 
Determination of Hepatic Endocannabinoid Content 
Endocannabinoids were measured from frozen liver tissues by stable isotope dilution 
liquid chromatography/tandem mass spectrometry (LC-MS/MS) as described previously 
(Mukhopadhyay et al., 2011) 
Western Blots 
Frozen liver samples were homogenized in RIPA lysis buffer (150 mM NaCl, 50 mM 
Tris, 1%NP-40). Protein concentrations were determined by means of bicinchoninic acid 
method using bovine serum albumin as standard (Pierce, Rockford, USA). 20 μg of protein 
was loaded from each sample onto 4-20% polyacrylamide gel. After separation by 
electrophoresis, proteins were transferred (Trans-Blot Turbo Blotting System, BioRad, 
Hercules, CA, USA) onto the PVDF membrane. Successful transfer was controlled by using 
Ponceau dye. The membrane was blocked with 5% non-fat dry milk in 0.05% TBS-T for 1 
hour at room temperature. After the blocking step, the membrane was incubated with a 
primary antibody (dissolved in 1% non-fat dry milk–TBS-T, 1:1000 dilution) against either 
SIRT-1 (Cell Signaling Technology, Danvers, MA, USA), PPAR-ɑ  (Abcam, Cambridge, 
MA, USA), or Acetyl-Lysine (Cell Signaling Technology, Danvers, MA, USA) for 2 h at 
room temperature, followed by washing with 0.05% TBS-T (3 × 10 min). After washing, the 
membrane was incubated with a secondary antibody (horseradish peroxidase-conjugated 
affinity purified goat anti-rabbit, 1/5000 dilution) in 1% non-fat dry milk in TBS-T for 1 h at 
room temperature. Then the membrane was washed again 3 times for 10 min. For detection 
of the bands, the membrane was incubated with ECL reagent (SuperSignal West Pico 
Substrate, Thermo Scientific - Pierce, Rockford, IL, USA) for 5 min and the signal was 
recorded in a gel documentation system (Versadoc 4000MP, Bio-Rad Imaging System, 
Hercules, USA). Band densities were evaluated by using Quantity One software (Bio-Rad 
Imaging System, Hercules, USA). Loading control was done by determining the actin content 
of each sample. Briefly, after stripping the membrane, it was probed with a primary antibody 
directly conjugated with HRP that recognizes actin (1/10,000 dilution - Abcam, Cambridge, 
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MA, USA) for 1 h at room temperature, followed by washing with TBS-T. Actin band 
visualization and evaluation of band densities were done as described above. There was no 
significant difference in actin between the groups. 
Statistical Analysis 
All the values are represented as mean  ±  SEM. Statistical analysis of the data was 
performed by one or two-way analysis of variance (ANOVA) followed by Tukey's post-hoc 
test for multiple comparisons, as appropriate. The analysis was conducted using GraphPad-
Prism4 software. P  <  0.05 was considered statistically significant. 
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Results 
β-caryophyllene treatment protects against alcoholic steatohepatitis 
We aimed to study the potential hepatoprotective action of BCP in setting of alcoholic 
liver disease. We employed the chronic plus binge ethanol feeding model, developed in the 
National Institute on Alcohol Abuse and Alcoholism (Bertola et al., 2013a), resembling 
major pathologic features of early alcoholic liver disease, involving hepatocyte injury, pro-
inflammatory alterations, and steatosis. BCP was administered daily during the course of 
Liber-DeCarli alcohol feeding protocol and at the end of the feeding period it was given 1 
hour prior to binge ethanol treatment (Fig.1. A). BCP treatment significantly alleviated binge 
alcohol-induced liver injury, as reflected by a decrease in serum ALT levels (Fig.1. B), and 
normalized the histopathological signs of alcoholic steatohepatitis (ballooning of hepatocytes, 
microvesicular steatosis, and neutrophil inflammatory infiltrates/loci) (Fig.1. C), and 
attenuated oxidative tissue injury, as reflected by reduced amount of 4-hydroxy-nonenal 
accumulation (Fig. 1. D).  
β-caryophyllene treatment prevents the pro-inflammatory phenotypic switch of hepatic 
macrophages upon chronic plus binge ethanol feeding 
Hepatic macrophage population undergoes a major phenotypic switch during the 
course of alcohol feeding (Wang et al., 2014). In a healthy control liver, a mixed population 
of larger and smaller Kupffer cell population is present: larger, spindle-shaped peri-sinusoidal 
macrophages are involved in phagocytosis and are less prone to activation, while the smaller, 
round-shaped peri-central macrophage population is more prone to activation and pro-
inflammatory cytokine and reactive oxygen species production (Laskin et al., 2001). To 
characterize macrophage morphology, we employed the pan-macrophage marker ionized 
calcium-binding adapter molecule (Iba-1) (Rehg et al., 2012). As an actin cross-linking 
protein, being involved in cytoskeletal reorganization, immunohistochemical detection of 
Iba-1 gives a sharp and detailed picture of macrophage morphology (Fig. 2. A) (Kohler, 
2007) in comparison to staining for cell membrane-specific markers F4/80 or CD68 (Fig. 2. 
B and Supplementary Fig. 1.). Accordingly, we detected the presence of the large Kupffer 
cells along the hepatic sinuses with arborized morphology both in the vehicle and BCP 
treated pair-fed groups (Fig. 2. A). However, upon ethanol-feeding we detected small, round-
shaped macrophages with less arborized morphology, resembling `M1`-type of morphology. 
BCP treatment partially prevented this morphological switch: large macrophages with 
arborization were present along the hepatic sinusoids (Fig. 2. A and B).  
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In line with the above observations, mRNA markers of tissue-resident macrophages, F4/80, 
CD68, and Iba-1 were down-regulated due to chronic plus binge ethanol feeding, an effect 
that was mitigated by BCP treatment (Fig.3. A). In addition CD11b expression, a marker of 
pro-inflammatory lymphocytes (mainly monocytes and macrophages) showed a striking 
increase in the ethanol-fed groups, that was attenuated by BCP treatment (Fig.3. A).  
Ethanol-fed mice displayed significant induction of `M1` markers of macrophage 
activation, including IL1ß, IL-6 and the chemokines, chemokine ligand 2 (CCL2 – MCP-1), 
and CXCL-2 (MIP-2). In addition, there was also a parallel induction of genes characteristic 
of an alternative `M2` activation signature, such as upregulation of arginase 1 (Arg1) and 
cluster of differentiation 163 (CD163), both attenuated by BCP treatment (Fig.3. B). Other 
markers of `M2` activation, like mannose receptor C type 2 (Mrc2), macrophage galactose-
type C-type lectin 1 (MGL1/CD301), C-type lectin domain family 7 member A (Clec7a), and 
IL-10 showed down-regulation, that was attenuated by BCP treatment only in the case of IL-
10 (Fig.3. C). These findings show that chronic alcohol feeding promotes polarization of 
Kupffer cells toward a mixed M1/M2 phenotype, an effect that is minimized by BCP 
treatment mainly in the case of `M1` activation.  
β-caryophyllene treatment prevents vascular inflammation and subsequent hepatic 
neutrophil infiltration due to chronic plus binge ethanol feeding 
Neutrophil infiltration is a key pathologic finding in alcoholic hepatitis and has been 
shown to closely correlate with the severity of alcoholic hepatic injury (Bertola et al., 2013b; 
Dominguez et al., 2009). Immunohistochemical staining for the neutrophil marker Ly6G 
confirmed that a large number of neutrophils had infiltrated the livers of chronic plus binge 
ethanol-fed mice, compared with control pair-fed mice. This effect of ethanol feeding was 
largely attenuated by BCP treatment (Fig. 4. A and B). Chronic plus binge ethanol feeding 
also led to a marked up-regulation of hepatic mRNA expression of the neutrophil marker, 
Ly6G (Fig. 4. C).  
To further investigate how chronic plus binge ethanol feeding leads to infiltration of 
neutrophils into the liver, hepatic expression of several vascular and tissue adhesion 
molecules were examined, reflecting vascular inflammatory processes. Chronic plus binge 
ethanol feeding resulted in the induction of ICAM-1, E-selectin, and P-selectin, which were 
significantly attenuated by BCP treatment (Fig. 4. D).  
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β-caryophyllene treatment prevents alcoholic steatosis and preserves PPAR-ɑ -
dependent signaling 
Daily administration of BCP prevented ethanol-feeding-induced development of 
microvesicular steatosis, as shown by oil red o staining on fresh frozen liver sections (Fig. 5. 
A). Quantification of liver triglycerol content confirmed the beneficial effect of BCP 
treatment on alcohol-induced hepatic lipid accumulation (Fig. 5. B). Since BCP and its 
metabolites have been proposed to affect cyclooxygenase-2 (COX2) and fatty acid amide 
hydrolase (FAAH) activity (Chicca et al., 2014), we aimed to measure endocannabinoids and 
related lipids in pair-fed mice treated either with vehicle or BCP (10 mg/kg). None of the 
measured lipids showed changes due to BCP treatment (anandamide: 0.90±0.06 fmol/mg in 
vehicle vs. 1.12±0.18 fmol/mg in BCP treated livers; 2-arachidonoylglycerol: 1.43±0.23 
pmol/mg in vehicle vs. 1.41±0.46 pmol/mg in BCP treated livers; oleoylethanolamide: 
13.66±1.38 fmol/mg in vehicle vs. 15.56±1.98 fmol/mg in BCP treated livers; arachidonic 
acid: 0.53±0.03 pmol/mg in vehicle vs. 0.41±0.12 pmol/mg in BCP treated livers ), 
implicating that the hepatoprotective effect of BCP is not related to COX2 or FAAH 
inhibition.  
Ethanol metabolism results in increased acetyl-CoA formation, with concomitant 
protein-acetylation and thereby leading to reprogramming of intermedier metabolism 
(Shepard et al., 2009). Sirtuins (SIRT) are NAD
+
-dependent protein deacetylase enzymes, 
capable of removing acetyl groups from proteins, and thereby preventing the development of 
alcoholic (Yin et al., 2014) and non-alcoholic fatty liver disease (Li et al., 2014). In line with 
these, we detected an increase in overall lysine acetylation in chronic plus binge ethanol-fed 
group that was attenuated by BCP treatment (Fig. 6. A). The increased acetylation pattern 
seen in ethanol-fed livers was paralleled by a decrease in SIRT-1 protein level, however, 
SIRT-1 expression seems to be not influenced by BCP treatment.  
We detected a massive reduction both in protein (Fig. 6. B) and mRNA levels of 
PPAR-ɑ  (Fig. 6. C) due to ethanol feeding, which was mitigated by BCP treatment. In line 
with this observation BCP treatment preserved the expression of PPAR-ɑ -related mRNA 
targets (peroxisome proliferator-activated receptor gamma coactivator 1- beta - PGC-1ß, 
glucose-6-phosphatase – G6PC, phosphoenolpyruvate carboxykinase 1 - Pck1, 
phosphofructokinase - PFK, and 3-hydroxy-3-methylglutaryl-CoA synthase 2 – HMGCS2) 
upon chronic plus binge ethanol feeding (Fig. 6. D and E). Interestingly, we detected a 
massive ethanol-feeding-induced up-regulation of a known PPAR-ɑ  target gene, the 
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fibroblast growth factor 21 (FGF21). However, this effect was markedly attenuated by BCP 
treatment (Fig. 6. F) 
The beneficial effects of β-caryophyllene treatment against alcoholic steatosis are 
attenuated in CB2 deficient mice 
Since BCP has been proposed to act on potential targets (SIRT-1, PPAR-ɑ , COX-2) 
other than CB2 receptor, we aimed to test, if there is any protective effect of BCP treatment 
in CB2 receptor deficient mice. We were not able to detect any marked effect of BCP 
treatment on macrophage morphology in ethanol-fed CB2 deficient mice (Fig. 7. A). This 
was further substantiated by the analysis of expression of F4/80 and CD11b, which were not 
affected by BCP treatment in CB2 knock-out mice (Fig. 7. B).  
We observed mild steatosis even in control pair-fed CB2 deficient mice. There was a 
significant induction of microvesicular steatosis in ethanol-fed CB2 deficient mice, however, 
this was not affected by BCP treatment (Fig. 7. C). On examining PPAR-ɑ  expression and 
PPAR-ɑ -related targets, we saw that effects observed in wild type ethanol-fed and BCP 
treated mice were lost in CB2 deficient mice (Fig. 7. D).  
Pharmacokinetic properties of β-caryophyllene 
BCP reached comparable serum (Fig.8. A), hepatic (Fig.8. B) and brain levels (Fig.8. 
C) in both ethanol-fed and pair-fed animals. BCP tissue concentrations indicated a 50-fold 
higher distribution in liver compared to brain. In addition BCP showed good oral 
bioavailability in comparison to the used intraperitoneal administration (Fig.8. D).  
Discussion 
In the present study we demonstrate that treatment with the dietary phytochemical 
BCP exerts marked hepatoprotective effects in the setting of chronic liver injury induced by 
chronic and binge alcohol feeding in mice. We show that 1) in the chronic and binge alcohol-
induced liver injury model BCP attenuates the pro-inflammatory phenotypic `M1` switch of 
Kupffer cells and 2) BCP treatment reduces expression of tissue and vascular adhesion 
molecules ICAM-1, E-Selectin and P-Selectin, as well as consequent neutrophil infiltration; 
3) BCP beneficially influences alcohol-induced hepatic metabolic dysregulation (steatosis, 
protein hyperacetylation, and PPAR-ɑ  signaling); 4) these protective effects of BCP involve 
CB2 receptor activation.  
CB2 is primarily expressed on immune and immune derived cells, including the 
Kupffer cells of the liver (Cao et al., 2013; Pacher et al., 2011; Teixeira-Clerc et al., 2010). 
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Activation of CB2 receptors mediate anti-inflammatory actions, limiting inflammatory and 
subsequent oxidative/nitrative tissue injury and organ damage (Pacher et al., 2011). 
Resident macrophages of the liver (Kupffer cells), account approximately for 10–15% 
of all liver cells. These cells are localized along the sinusoidal space of Disse anchored to 
endothelial cells by long cytoplasmic processes, being involved in maintaining tissue 
homeostasis and providing immunosurveillance. In addition, they also play a protective role 
in promoting liver regeneration (Meijer et al., 2000). Kupffer cells may become activated by 
a variety of stimuli that trigger innate immunity, involving endogenous molecules released 
during hepatocyte injury (e.g. hyaluronic acid, heparin sulfate, high-mobility group box 1 
(HMGB1), or heat shock proteins) (Tsung et al., 2005). In addition, Kupffer cell activation 
might be triggered by environmental toxins, as in the case of alcoholic steatohepatitis by 
ethanol and its metabolites or by endotoxin, absorbed due to increased gastrointestinal 
permeability. Pathologically over-activated macrophages, as seen in alcoholic-, and in non-
alcoholic fatty liver disease, may further aggravate tissue injury and inflammation, leading to 
liver failure. Since BCP has been proposed to protect the colonic mucosa against dextran 
sulfate-induced colitis (Bento et al., 2011; Cho et al., 2007), it is possible that BCP exert 
similar protection against ethanol-induced mucosal damage and thereby also attenuates 
endotoxin translocation from the gut to the portal circulation (Bode et al., 1987).  
Kupffer cells consist of three major different subsets; the CD11b
+
 cells, and CD68
+
 
cells overlapping with CD32
+
 cells, representing precursors of CD68+ cells (expressing stem 
cell markers, such as c-kit (CD117) and CD34 (Kinoshita et al., 2010). Detailed flow 
cytometric and immunohistochemical studies also revealed that the CD68
+
 cells are large and 
spindle-shaped, while the CD11b
+
 cells are small and round or oval-shaped (Ikarashi et al., 
2013). While large macrophages are more phagocytic and generate increased quantities of 
lysosomal enzymes, the smaller macrophages release more reactive oxygen species, and 
appear to be more susceptible to `M1`-type of activation and cytokine production. 
Interestingly, we found that chronic and binge alcohol feeding resulted in pro-inflammatory 
phenotypic switch in liver Kupffer cells, which was attenuated by BCP treatment. 
Experimental CB2 agonists (e.g.: JWH-133, HU910, HU308) have been shown to 
favorably affect overall hepatic macrophage activation upon chronic alcohol exposure 
(Louvet et al., 2011) and hepatocyte injury (Batkai et al., 2007; Horvath et al., 2012a; Rajesh 
et al., 2008). However, not a single CB2 agonist is approved for clinical testing in liver 
disease yet. In this study, we demonstrate that the FDA approved food additive BCP, which is 
present in various food and medicinal plants, as well as in cannabis essential oil, exerts 
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hepatoprotective effects in a model of alcohol-induced chronic liver injury. The observed 
protective effects were attenuated in CB2 knockout mice indicating involvement of CB2. To 
increase the translational potential of our study, we also tested the pharmacokinetic properties 
of oral and intraperitoneal BCP administration both in healthy and in ethanol-fed mice. BCP 
was orally bioavailable, and ethanol-feeding did not interfere with its kinetics (e.g. 
absorption, or metabolism). The BCP dose used in our study in mice (10 mg/kg) is 
convertible to a human equivalent dose of approximately 0.8-1 mg/kg/day for adult human 
subjects (Nair et al., 2016). Based on the mouse pharmacokinetics data, repeated oral dosing 
of BCP might be desirable, the benefit of which remains to be tested.  
Our results also suggest that BCP has beneficial properties on intermediary 
metabolism in ethanol-fed animals, potentially by decreasing pro-inflammatory cytokine 
expression in a CB2-dependent manner and thereby preserving PPAR-ɑ -related signaling 
that is characteristic for the healthy liver.  
An intriguing field of investigation is how pro-inflammatory alterations influence 
hepatic intermediary metabolism. It is now well established that pro-inflammatory cytokines 
(IL-1ß or TNFɑ ) may profoundly affect hepatic lipid and glucose metabolism in a paracrine 
manner (Louvet et al., 2011; Stienstra et al., 2010). Stienstra et al. has shown that IL-1ß is 
capable to suppress human and mouse PPAR-ɑ  promoter activity and in parallel interferes 
with the ability of PPAR-ɑ  to activate transcription of target genes (Stienstra et al., 2010). 
We found that alcohol markedly impaired PPAR-ɑ  signaling and increased lipid 
accumulation in the liver, which were significantly attenuated by BCP treatment, however, 
the effects seem to relate to BCP-induced CB2 activation rather than to a direct PPAR-ɑ  
mediated effect.  
 During hepatic ethanol metabolism, liver mitochondria convert acetate into acetyl-
CoA that is further processed in the citric acid cycle. However, due to ethanol metabolism, 
there is an increased level of NADH that inhibits further metabolism of the acetyl-CoA by the 
citric acid cycle. In addition excess NADH inhibits gluconeogenesis by preventing the 
oxidation of lactate to pyruvate, leading to accumulation of lactate (lactic acidosis), and 
causing hypoglycemia (Tsai et al., 2015). Further consequences of hepatic acetyl-CoA 
accumulation involves increased protein acetylation (histones, transcription factors – 
SREBP1c, FOXO1, FOXO3, PGC1ɑ  - (Shepard et al., 2009)), ketone body formation, 
increased fatty acid synthesis and fat storage, and buildup of acetaldehyde. Increased 
production of acetaldehyde forms covalent bonds with many important functional groups in 
proteins, impairing protein function. It may also react with phospholipids and arachidonic 
Varga et al.  
 
This article is protected by copyright. All rights reserved. 
acid, which triggers lipid peroxidation reactions promoting hepatocyte cell death. 
Consistently with the above, we found increased protein acetylation and lipid peroxidation 
(4HNE formation) in livers of ethanol-fed groups, which were attenuated by BCP treatment. 
Collectively, our results demonstrate that BCP treatment exerts beneficial effects against liver 
injury induced by chronic plus binge ethanol feeding by attenuating the Kupffer cell-
mediated pro-inflammatory response (activation and/or pro-inflammatory phenotypic `M1` 
switch), neutrophil-mediated oxidative/nitrative stress/injury, vascular inflammation 
(expression of vascular adhesion molecules), and hepatic metabolic dysregulation (steatosis, 
protein hyperacetylation, and PPAR-ɑ  signaling). Our results also indicate that these in vivo 
protective effects of BCP against alcohol-induced hepatic injury may involve, at least in part, 
CB2 mediated mechanisms. Our study may have immediate translational potential in liver 
disease since BCP is an FDA approved food additive in humans.  
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Figure Legends 
 
Fig. 1. Protective effect of β-caryophyllene treatment against chronic plus binge ethanol 
feeding induced hepatic injury 
(A) Experimental alcohol- and isocaloric pair-feeding protocol combined with single 
ethanol/maltodextrin binge at the end of the 10 days long diet. Green arrows indicate daily 
drug treatments (vehicle or 10 mg/kg BCP). Red arrow represents single ethanol binge 
treatment, while the blue arrow represents an isocaloric maltodextrin gavage.  
(B) Determination of liver injury by measurement of ALT enzyme activity, and histological 
assessment of hepatic pathologic alterations (C) on hematoxylin-eosin stained liver sections 
in vehicle or BCP treated pair-fed or ethanol-fed mice, respectively. 
(D) Assessment of oxidative stress in vehicle or BCP treated pair-fed or ethanol-fed mice, by 
histological staining for 4-hydroxy-nonenal.  
Results are mean ± S.E.M. n= 8. *p<0.05 vs. pair-fed with vehicle treatment, #p<0.05 vs. 
ethanol-fed with vehicle pretreatment. 
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Fig. 2. β-caryophyllene prevents chronic plus binge ethanol feeding-induced 
morphological changes in hepatic macrophages  
(A) Representative confocal scanning microscopic images of Iba-1 positive hepatic 
macrophages from pair-fed and ethanol-fed mice either treated with vehicle or BCP (10 
mg/kg). (B) Representative light microscopic images of F4/80 positive hepatic macrophages 
from pair-fed and ethanol-fed mice either treated with vehicle or BCP (10 mg/kg).  
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Fig. 3. β-caryophyllene prevents chronic plus binge ethanol feeding-induced pro-
inflammatory phenotypic switch of hepatic macrophages  
(A) Gene expression of classic macrophage markers, F4/80, CD68, Iba-1, and CD11b in the 
liver of pair-fed and ethanol-fed mice either treated with vehicle or BCP (10 mg/kg). (B) 
Gene expression of pro-inflammatory macrophage activation markers (M1 phenotype), IL-1-
β, IL-6, CCL2, CCL4, and CXCL2 in the liver of pair-fed and ethanol-fed mice either treated 
with vehicle or BCP (10 mg/kg). (C) Gene expression of alternative macrophage activation 
markers (M2 phenotype), Arg-1, Mrc-2, Mgl-1, CD163, Clec7a, and IL-10 in the liver of 
pair-fed and ethanol-fed mice either treated with vehicle or BCP (10 mg/kg).  
Results are mean ± S.E.M. n= 6. *p<0.05 vs. pair-fed with vehicle treatment, #p<0.05 vs. 
ethanol-fed with vehicle pretreatment. 
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Fig. 4. β-caryophyllene prevents chronic plus binge ethanol feeding-induced hepatic 
vascular inflammation and neutrophil infiltration 
(A) Immunohistochemical detection of Ly6G positive neutrophil granulocytes from pair-fed 
and ethanol-fed mice either treated with vehicle or BCP (10 mg/kg). (B) Average number of 
neutrophil granulocytes on high power field microscopic images taken from histological 
sections of the livers of pair-fed and ethanol-fed mice either treated with vehicle or BCP (10 
mg/kg). (C) Gene expression of the neutrophil marker Ly6G in the liver of pair-fed and 
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ethanol-fed mice either treated with vehicle or BCP (10 mg/kg). (D) Gene expression of pro-
inflammatory vascular adhesion molecules, ICAM-1, E-selectin, and P-selectin in the liver of 
pair-fed and ethanol-fed mice either treated with vehicle or BCP (10 mg/kg).  
Results are mean ± S.E.M. n= 6. *p<0.05 vs. pair-fed with vehicle treatment, #p<0.05 vs. 
ethanol-fed with vehicle pretreatment. 
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Fig. 5. β-caryophyllene prevents chronic plus binge ethanol feeding-induced hepatic 
steatosis 
(A) Histochemical detection of neutral lipids (Oil Red O staining) in fresh frozen liver 
sections of pair-fed and ethanol-fed mice either treated with vehicle or BCP (10 mg/kg). (B) 
Quantitative determination of triglycerol content in the livers of pair-fed and ethanol-fed mice 
either treated with vehicle or BCP (10 mg/kg).  
Results are mean ± S.E.M. n= 6.*p<0.05 vs. pair-fed with vehicle treatment, #p<0.05 vs. 
ethanol-fed with vehicle pretreatment. 
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Fig. 6. β-caryophyllene prevents chronic plus binge ethanol feeding-induced loss of 
PPARα expression, decreases protein hyperacetylation and promotes PPARα-
dependent signaling 
Western blot analysis of hepatic protein lysine acetylation (A and B) and PPARα protein 
expression (B) in the liver of pair-fed and ethanol-fed mice either treated with vehicle or BCP 
(10 mg/kg). (C) Gene expression of PPAR transcription factors, PPARα, PPARγ, and PPARδ 
in the liver of pair-fed and ethanol-fed mice either treated with vehicle or BCP (10 mg/kg). 
(D) Gene expression of PPAR coactivators, PGC1-α, and PGC1-β in the liver of pair-fed and 
ethanol-fed mice either treated with vehicle or BCP (10 mg/kg). (E) Gene expression of 
PPARα signaling-related transcripts, G6PC, PCK-1, PFK, HMGCS2 and (F) FGF-21 in the 
liver of pair-fed and ethanol-fed mice either treated with vehicle or BCP (10 mg/kg).  
Results are mean ± S.E.M. n= 6. *p<0.05 vs. pair-fed with vehicle treatment, #p<0.05 vs. 
ethanol-fed with vehicle pretreatment. 
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Fig. 7. β-caryophyllene-induced protection against alcoholic steatohepatitis is attenuated 
in CB2 receptor deficient mice 
(A) Confocal scanning microscopic images of Iba-1 positive hepatic macrophages from pair-
fed wild type CB2 receptor deficient mice and from ethanol-fed CB2 receptor deficient mice 
either treated with vehicle or BCP (10 mg/kg). (B) Gene expression of classic macrophage 
markers, F4/80, and the pro-inflammatory vascular adhesion molecule ICAM-1 and the 
monocyte marker CD11b in the liver of pair-fed and ethanol-fed CB2 receptor deficient mice 
either treated with vehicle or BCP (10 mg/kg). (C) Histochemical detection of neutral lipids 
(Oil Red O staining) in fresh frozen liver sections of pair-fed wild type CB2 receptor 
deficient mice and from ethanol-fed CB2 receptor deficient mice either treated with vehicle 
or BCP (10 mg/kg). (D) Gene expression of PPARα, PGC1-β and FGF21 in the liver of pair-
fed and ethanol-fed CB2 receptor deficient mice either treated with vehicle or BCP (10 
mg/kg).  
Results are mean ± S.E.M. n= 6. *p<0.05 vs. sham with vehicle pretreatment. 
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Fig. 8. Pharmacokinetic properties of β-caryophyllene 
(A) Determination of serum, hepatic (B), and brain (C) tissue levels of BCP 30, 60, 180, and 
360 min after 10 day long chronic administration (10 mg/kg daily) to either pair-fed or 
ethanol-fed animals. (D) Determination of serum levels of BCP 30, 60, 180, and 360 min 
after BCP administration (single dose of 10 mg/kg given intraperitoneally [i.p.] or orally).  
Results are mean ± S.E.M. n= 3.  
 
